Teriparatide

Introduction Overview

Generic Name

teriparatide

Brand Name

Forteo

Dosage Form

injection

Drug Class

Parathyroid hormone and analogs

Pharmacokinetics

Absorption: Teriparatide administered by subcutaneous injection is rapidly absorbed, with peak plasma concentrations occurring within 30 minutes of dosing. Bioavailability following subcutaneous administration approaches 95%, allowing efficient systemic exposure. The rapid absorption supports once-daily dosing to achieve effective receptor engagement on target bone cells. Clinical pharmacokinetic studies demonstrate dose-proportional increases in plasma levels across the prescribed dosing range, ensuring predictable therapeutic effects. Factors such as injection site and blood flow may impact absorption kinetics but are clinically managed through administration guidelines.

Distribution: After systemic absorption, teriparatide is widely distributed throughout extracellular fluid compartments. Teriparatide exhibits moderate protein binding and is primarily localized to bone and kidney tissues where parathyroid hormone receptors are expressed. The volume of distribution approximates extracellular fluid volume, facilitating interaction with osteoblasts and renal tubular cells. Teriparatide crosses minimal barriers beyond the vascular compartment, as it is a peptide with limited tissue penetration beyond targeted receptor sites.

Metabolism: Teriparatide is metabolized primarily via proteolytic degradation by endopeptidases in the liver, kidneys, and plasma, resulting in inactive peptide fragments. Metabolic clearance occurs through general peptide catabolism rather than cytochrome P450 pathways, minimizing potential for hepatic drug interaction. Metabolism is rapid, consistent with the short half-life of the drug, allowing transient pharmacodynamic activity after daily injection. No active metabolites have been identified. Impaired renal or hepatic function may modestly affect peptide metabolism kinetics.

Elimination: Teriparatide and its metabolites are eliminated predominantly by renal excretion following proteolytic cleavage. The plasma half-life of teriparatide is approximately 1 hour, supporting once-daily subcutaneous administration. Renal clearance accounts for the primary elimination route of peptide fragments, with minimal unchanged peptide excretion. In patients with moderate renal impairment, clearance may be moderately delayed, but no dosage adjustment is generally required. Hepatic dysfunction does not significantly influence elimination due to peptide catabolic routes. The terminal elimination phase allows return to baseline prior to subsequent dosing.

Dosage Forms

Available Dosage Forms: Forteo is available exclusively as a prefilled multi-dose injection pen designed for subcutaneous administration. Each pen contains 28 individual doses at a strength of 20 micrograms per dose of teriparatide. The pen is a user-friendly delivery device that facilitates self-administration by patients, featuring a dial-dose mechanism and needle attachment system.

Dosages for Adults and Adolescents: The recommended dose for adults with osteoporosis, including postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis, is 20 mcg administered once daily via subcutaneous injection. The injection site may be the thigh or abdominal wall. Therapy duration is generally recommended for up to 2 years, with continuation only if fracture risk remains high.

Specific Patient Populations: Forteo is contraindicated in pediatric populations and individuals with open epiphyses due to lack of safety and efficacy data. No dosage adjustments are typically required for elderly patients or patients with mild to moderate renal impairment. Supplementation with calcium and vitamin D is advised in patients with inadequate dietary intake or absorption. The delivery system is designed for ease of use in populations requiring self-administration, including those with limited manual dexterity.

Additional Formulation Information: Teriparatide injection solution is a sterile, clear, colorless liquid formulated with inactive ingredients including glacial acetic acid, sodium acetate anhydrous, mannitol, metacresol, and water for injection, adjusted to pH 4. The formulation is preservative-containing and stored refrigerated between 2°C to 8°C. The medication must be protected from light and not frozen.

Mechanism Of Action

Teriparatide is a recombinant form of the biologically active 1-34 amino acid fragment of human parathyroid hormone (PTH), which is pivotal in calcium homeostasis and bone metabolism. This fragment retains full biological potency, enabling targeted activation of the parathyroid hormone 1 receptor (PTH1R) located predominantly on osteoblasts and renal tubular cells. Upon binding PTH1R, teriparatide activates intracellular signaling cascades primarily through the cyclic adenosine monophosphate (cAMP) and phospholipase C pathways.

At the cellular level, teriparatide promotes osteoblastic activity by stimulating differentiation, proliferation, and survival of osteoblasts, the bone-forming cells responsible for synthesizing osteoid and orchestrating mineralization. The intermittent daily administration pattern preferentially enhances anabolic bone formation rather than bone resorption, which contrasts with the continuous elevated PTH levels observed in hyperparathyroidism that favor bone loss. Teriparatide also modulates the bone remodeling process by increasing osteoblast numbers and function, leading to increased bone matrix deposition.

Biochemically, teriparatide influences calcium metabolism by promoting renal calcium reabsorption and increasing intestinal calcium absorption indirectly via vitamin D activation. The net effect of teriparatide is increased bone mineral density (BMD) particularly in trabecular-rich sites like vertebrae and cortical bone, enhancing bone strength and reducing fracture risk. Clinical studies have demonstrated marked improvements in BMD and reduction in vertebral and non-vertebral fractures in treated patients compared to controls.

The mechanistic profile of teriparatide distinguishes it from antiresorptive therapies such as bisphosphonates and denosumab, which primarily inhibit osteoclast-mediated bone resorption. Teriparatide’s anabolic mechanism facilitates bone rebuilding, making it especially useful for patients with severe osteoporosis or those who have failed other therapies. Ongoing research continues to explore teriparatide’s effect on bone microarchitecture and quality improvements, affirming its role as a potent anabolic agent in clinical osteoporosis management.

Pharmacological Actions

Anabolic agent that stimulates new bone formation
Activates parathyroid hormone 1 receptor (PTH1R) on osteoblasts
Increases osteoblast number and activity to enhance bone mineral density
Modulates calcium homeostasis by increasing renal calcium reabsorption
Promotes intestinal calcium absorption indirectly via vitamin D pathways
Inhibits osteoblast apoptosis, prolonging bone-forming cell lifespan
Enhances bone remodeling balance favoring bone formation over resorption with intermittent dosing
Improves bone microarchitecture and mechanical strength
Reduces incidence of vertebral and non-vertebral fractures in osteoporosis
Facilitates rapid onset of action compared to antiresorptive therapies
Restores bone mass in glucocorticoid-induced osteoporosis
Stimulates synthesis of bone matrix proteins
Has systemic effects on calcium metabolism including elevation of serum calcium transiently
Does not undergo significant cytochrome P450 metabolism, limiting drug interaction potential

Therapeutic Or Clinical Uses

Treatment of osteoporosis in postmenopausal women at high risk for fracture
Treatment of primary or hypogonadal osteoporosis in men at high risk of fractures
Management of osteoporosis induced by long-term glucocorticoid therapy in both men and women
Increase bone mineral density and strength to reduce fracture risk
Use in patients who are unable to tolerate or have contraindications to other osteoporosis treatments
Prevention of vertebral and non-vertebral fractures in high-risk populations
Adjunctive therapy with calcium and vitamin D supplementation for maximal benefit
Short-term anabolic therapy intended for up to two years
Treatment option following failure or intolerance to bisphosphonates or other antiresorptives
Improvement of bone microarchitecture in osteoporotic patients
Used in patients with osteoporosis complicated by prior fractures
May be considered in patients with renal impairment with caution
Useful in cases where rapid improvement in bone density is clinically required
Promotes bone repair in glucocorticoid-induced bone loss
Facilitates personalizable treatment with self-administered injection pens

Side Or Adverse Effects

Injection site reactions including pain and erythema
Arthralgia (joint pain)
Nasopharyngitis leading to runny nose and upper respiratory symptoms
Hypertension or elevated blood pressure
Nausea and gastrointestinal discomfort
Dizziness and light-headedness, sometimes post-injection
Headache of varying intensity
General weakness, fatigue, or tiredness
Increased cough frequency
Pharyngitis and sore throat
Constipation and indigestion
Diarrhea in some patients
Hypercalcemia presenting with symptoms such as confusion, muscle weakness, increased thirst, and frequent urination
Possible allergic reactions including hives, swelling, and breathing difficulty
Potential for osteosarcoma development observed in animal studies, though not confirmed in humans

Precautions

Use caution in patients with history of bone malignancies or metabolic bone diseases other than osteoporosis
Assess calcium levels prior to and during treatment to avoid hypercalcemia
Avoid use in patients with Paget’s disease or unexplained elevations in alkaline phosphatase
Not indicated for use in pediatric populations due to open growth plates
Patients should remain well hydrated to reduce calcium-related side effects
Monitoring for signs of dizziness or orthostatic hypotension post-injection is advised
Discontinue use if signs of hypersensitivity occur
Advise patients to avoid smoking and heavy alcohol use, which impair bone density
Supplement diet with calcium and vitamin D if dietary intake is inadequate
Limit duration of therapy to 2 years due to potential risk of bone cancer
Use cautiously in patients with renal impairment
Educate patients on proper injection technique and site rotation to minimize injection site adverse effects
Pregnancy category not established; avoid use in pregnancy
Breastfeeding safety not established; recommend against breastfeeding while on therapy
Advise patients on potential dizziness and to avoid hazardous activities until response is known

Warnings

Risk of osteosarcoma observed in preclinical animal models; unknown if risk translates to humans
Contraindicated in patients with skeletal malignancies or prior radiation therapy involving the skeleton
Avoid use in patients with Paget’s disease or unexplained elevated alkaline phosphatase
Discontinue therapy if hypercalcemia develops
Patients should avoid smoking and heavy alcohol consumption during treatment to optimize bone health
Use only as prescribed and for recommended duration; excessive use may increase adverse effects
Monitor for orthostatic hypotension to prevent falls related to dizziness
Immediate medical attention is warranted for signs of severe allergic reactions
Stop treatment if new bone tumors or abnormal bone growths are detected
Careful patient selection is essential to minimize potential risks
Safety and efficacy not established beyond 2 years of use
Injection pen should be discarded after 28 doses to prevent dosing errors
Storage warnings: do not freeze and protect from heat and light exposure
Avoid transfer of medication to other delivery devices to prevent overdose
Report any unexpected adverse effects to healthcare provider promptly

Contraindication

Known hypersensitivity to teriparatide or any component of the formulation
Patients with Paget’s disease or other metabolic bone diseases apart from osteoporosis
History of osteosarcoma or other bone malignancies
Prior radiation therapy involving skeleton
Children and adolescents with open epiphyses (still growing bones)
Patients with hypercalcemia at baseline
Use during pregnancy due to unknown fetal risk
Breastfeeding women due to unknown excretion in milk
Patients with unexplained elevations of alkaline phosphatase
Use in patients with certain genetic disorders predisposing to bone cancer
Known hypersensitivity to any excipients like mannitol or metacresol
Severe renal impairment without clinical monitoring
Concomitant use with other parathyroid hormone therapies
Patients unable to self-administer or follow injection protocol safely
Patients with history of skeletal radiation or bone malignancies

Drug Interactions

Concomitant use with digoxin requires caution due to calcium effects on cardiac rhythm
Warfarin and other anticoagulants may have altered efficacy due to changes in calcium levels
Concurrent corticosteroids such as prednisone or methylprednisolone may antagonize anabolic effects
No significant cytochrome P450 mediated drug interactions expected
Use caution with other agents affecting bone metabolism or calcium homeostasis
Potential additive effects with calcium and vitamin D supplements
Avoid combining with other parathyroid hormone analogs
Use caution with cardiac glycosides due to risk of arrhythmia
Interactions with herbal supplements and over-the-counter vitamins affecting calcium balance may occur
Diuretics affecting calcium excretion could influence teriparatide effect
Monitor electrolyte levels when administered with other drugs affecting renal function
NSAIDs and analgesics do not significantly interact but monitor for adverse effects
Drug interactions in the elderly with polypharmacy require close monitoring
Adjust therapy appropriately if concomitant drugs impact bone metabolism
Inform healthcare providers of all medications to prevent unrecognized interactions

Preparations Of The Drug

Prefilled multidose injection pen with 20 mcg teriparatide per dose
28-dose pen designed for once-daily subcutaneous administration
Contains inactive ingredients: glacial acetic acid, sodium acetate (anhydrous), mannitol, metacresol, and water for injection
Formulated at a pH ~4 using hydrochloric acid or sodium hydroxide for adjustment
Delivered via a ready-to-use pen system with needle attachment for self-injection
Stored refrigerated at 2°C to 8°C (36°F to 46°F) prior to use
Single pen discarded after 28 injections or 28 days after first use
Do not freeze; discard if freezing occurs
Radiopaque needle may be used to assist proper injection technique
Packaging includes detailed patient instructions and safety information
Injection solution is clear, colorless, sterile, and preservative-containing
Protect from heat, light, and physical damage by storing in original carton
Needles provided separately and to be disposed of safely after use
Product approved and distributed by Lilly USA, LLC
Prefilled syringe or alternate presentations currently not marketed